Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.64 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385780 | 0.87 | GPR119 (0.67) | GPR119TLR9TLR7ACHECKS1B | |
| SCHEMBL2386443 | 0.86 | GPR119 (0.68) | GPR119TLR9TLR7KITACHE | |
| SCHEMBL31651589 | 0.85 | POLB (0.53) | GPR119POLBKITGBA1ACHE | |
| SCHEMBL31651638 | 0.84 | POLB (0.52) | GPR119TLR9TLR7POLBKIT | |
| SCHEMBL11359476 | 0.83 | POLB (0.55) | GPR119TLR9TLR7POLBKIT | |
| SCHEMBL31651776 | 0.83 | POLB (0.53) | GPR119TLR9TLR7POLBKIT | |
| SCHEMBL2384061 | 0.82 | GPR119 (0.63) | GPR119TLR9TLR7KITGBA1 | |
| SCHEMBL3882026 | 0.82 | GPR119 (0.54) | GPR119POLBKITGBA1ACHE | |
| SCHEMBL31651904 | 0.81 | GPR119 (0.53) | GPR119POLBKITGBA1 | |
| SCHEMBL2719501 | 0.81 | ACHE (0.45) | GPR119TLR9TLR7POLBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1608373-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083235-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | GPR119 686/4885TLR9 2347/4885TLR7 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.